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Methods: Patients with carbapenem nonsusceptible K. pneumoniae and E. coli in ICUs from
nine medical centers and eight regional hospitals in Taiwan were enrolled in 2012. Carbape-
nem nonsusceptibility was defined as a minimum inhibitory concentration of at least 2 mg/L
for imipenem or meropenem. Clinical characteristics and risk factors for 30-day mortality
were analyzed. Isolates were screened for antibiotic susceptibility and b-lactamase genes.
Results: A total of 66 cases infected (n Z 46) or colonized (n Z 20) with carbapenem non-
susceptible K. pneumoniae (n Z 60) and E. coli (n Z 6) were identified during the study
period. Nineteen isolates had genes that encoded carbapenemases (28.8%), including
Klebsiella pneumoniae carbapenemase-2 (KPC-2) (n Z 14), imipenemase-8 (IMP-8)
(n Z 1), Verona integron-encoded metallo-b-lactamase (VIM) (n Z 3), and New Delhi
metallo-b-lactamase-1 (NDM-1) (n Z 1). The in-hospital mortality associated with non-
susceptible K. pneumoniae and E. coli was 50%. The 30-day mortality of the 46 patients with
infection was 50%. Septic shock was the only independent risk factor for 30-day mortality in
patients with infection. The 30-day mortality rate was similar between patients with combi-
nation therapy and monotherapy.
Conclusion: Patients who acquired carbapenem nonsusceptible K. pneumoniae and E. coli in ICUs
have a high mortality rate. Further clinical study is needed to deal with this emerging challenge.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Carbapenems are potent and broad-spectrum b-lactam
antibiotics traditionally reserved for the treatment of the
most serious bacterial infections. The increasing preva-
lence of extended-spectrum b-lactamase (ESBL) producing
Enterobacteriaceae is contributing to the increased con-
sumption of carbapenems.1 Because of the widespread use
of carbapenems over the past decade, the emergence of
carbapenem-resistant Enterobacteriaceae (CRE) has
become an important challenge.2,3 The most common CRE
reported in the literature was Klebsiella pneumoniae, fol-
lowed by Escherichia coli and/or Enterobacter species.4,5
The estimated mortality rate ranged from 29% to 52% in
patients with CRE infections, and from 40% to 50% in
bloodstream infection.3,6
The two main mechanisms of carbapenem resistance are
acquisition of carbapenemase genes, such as Ambler class
A, B, and D b-lactamases; and a decrease in the uptake of
antibiotics by a qualitative or/and quantitative deficiency
of porin expression in association with overexpression of b-
lactamases that possess very weak affinity for carbape-
nems.7 The worldwide spread of Enterobacteriaceae
expressing carbapenemase now represents a significant
threat to public health and requires immediate efforts to-
ward early detection and infection control.8
In Taiwan, the rate of nonsusceptibility to ertapenem
among bloodstream isolates of K. pneumoniae increased from
0% in 2001 to 13.6% in 2008 [Clinical and Laboratory Standards
Institute (CLSI) 2010 criteria].9 Ertapenem-nonsusceptible K.
pneumoniaebacteremiawas associatedwithpoor outcome.10
The rate of nonsusceptibility to ertapenem in E. coli isolates
increased from 0.1% in 1999 to 1.7% in 2007 (CLSI 2009
criteria).11 The proportion of CRE isolates increased signifi-
cantly from 1.4% in 2003 to 4.5% in 2009 in intensive care units(ICUs), according to the Taiwan Nosocomial Infection Sur-
veillance system.12 Patients in ICUs are especially prone to
colonization and infection by CRE, and prolonged ICU stay is a
risk factor for the acquisition of CRE.13e15 In the first outbreak
of intra- and interhospital dissemination of Klebsiella pneu-
moniae carbapenemase-2 (KPC-2) producing K. pneumoniae
in Taiwan, 87.5% of the cases occurred in ICUs.16
Although CRE infections constitute a real clinical prob-
lem, few studies have focused on CRE infections in the ICU
setting. Therefore, we conducted a multicenter investiga-
tion of the clinical and microbiological characteristics of
patients who acquired carbapenem nonsusceptible K.
pneumoniae and E. coli in ICUs of Taiwanese hospitals.Methods
Study population
From January 2012 to December 2012, 17 hospitals in Taiwan
were involved in thestudy, includingninemedicalcenters (the
National Taiwan University Hospital, Taipei Veterans General
Hospital, Tri-ServiceGeneral Hospital, and LinkouChangGung
Memorial Hospital in the north; the China Medical University
Hospital in the center of the country; the Chi Mei Medical
Center, Kaohsiung Chang Gung Memorial Hospital, and Kaoh-
siung Medical University Hospital in the south; and the
Buddhist Tzu Chi General Hospital in the east), and eight
regional hospitals included the Keelung Chang Gung Memorial
Hospital, Taoyuan Armed Forces General Hospital, Hualien
Armed Forces General Hospital, Chiayi Chang Gung Memorial
Hospital, National Yang-Ming University Hospital, Taichung
Armed Forces General Hospital, Kaohsiung Armed Forces
General Hospital, and Kaohsiung Municipal Hsiaokang
Hospital.
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During the study period, carbapenem nonsusceptible K.
pneumoniae and E. coli isolates were collected from clin-
ical specimens sent for culture to the microbiological lab-
oratories of participating hospitals. A single strain was
selected per patient. Carbapenem nonsusceptibility was
defined as imipenem or meropenem minimum inhibitory
concentration (MIC) of at least 2 mg/L. The isolates
collected from each hospital were sent to the National
Health Research Institutes, Miaoli, Taiwan and were stored
at 70C in 10% glycerol Luria-Bertani medium prior to
analysis. A VITEK 2 automated system (bioMe´rieux, Marcy
l’Etoile, France) was used for bacterial identification.
MICs were determined by broth microdilution (Sensititre,
Trek Diagnostic Systems, Cleveland, OH, USA) for all antibi-
otics except tigecycline as described previously.17 The CLSI
M100-S22 interpretive breakpoints were used to interpret
the MIC results for all antimicrobial agents studied, except
tigecycline and colistin.18 The susceptibility to colistin was
defined based on the European Committee on Antimicrobial
Susceptibility Testing (susceptible, MIC  2 mg/L; resistant,
MIC > 2 mg/L) as described previously.19 The MICs for tige-
cycline were determined using the E-test (AB Biodisk, Solna,
Sweden) on Mueller-Hinton media, and susceptibility to
tigecycline was defined based on the Food and Drug Admin-
istration criteria (susceptible, MIC  2 mg/L; resistant,
MIC  8 mg/L) as described previously.20Data collection
The clinical data of patients with carbapenem non-
susceptible K. pneumoniae and/or E. coli isolated within 48
hours after admission to ICUs were retrospectively
collected. Patients <20 years and those with incomplete
medical records were excluded. Surveillance cultures were
not performed during the study period, and all isolates
were from clinical cultures. The study protocol received
hospital institutional review board approval.
Infection or colonization, and the probable infectious
source, were determined on the basis of microbiological re-
sults, medical record, and the judgments of two specialists in
infection. Medical recordswere reviewed to extract pertinent
information, including demographic characteristics, comor-
bid conditions, Charlson Comorbidity Index, duration of hos-
pital stay, duration of therapy for infection with individual
antimicrobial strains, ventilator status, and central venous
catheter or Foley catheter status at the time of bacterial
strains collection. The Acute Physiology and Chronic Health
Evaluation (APACHE) II score was used to assess severity of
illness at the time of bacterial strains collection.21 Definitive
antibiotic therapy was defined as antibiotics administered
initially and continued after the results of susceptibility
testing of cultures became known. Appropriate antimicrobial
therapy was defined as administration of one or more anti-
microbial agents to which the causative pathogen was sus-
ceptible in vitro after the onset of infection with an approved
route and dose appropriate for end-organ function. Antimi-
crobial therapy that did not meet this definition was consid-
ered inappropriate. Appropriate empirical antimicrobialtreatment referred to administration of in vitro active anti-
microbials against the study isolates, within 24 hours from
infection onset. Combination therapy was defined as admin-
istration of two antimicrobials with gram-negative activity for
at least 48 hours after the susceptibility results became
available, regardless of the in vitro susceptibility to each
agent. The primary outcome measure was the all-cause 30-
day mortality rate after the onset of infection.
Detection of genes encoding carbapenemase, AmpC
b-lactamase, and ESBLs, and outer membrane
protein analysis
Carbapenem nonsusceptible K. pneumoniae and E. coli iso-
lates were screened for carbapenem-hydrolyzing ß-lacta-
mase genes of Ambler class A (encoding Klebsiella
pneumoniae carbapenemase-2 (KPC-2), nonmetallo-enzyme
carbapenemase (NMC), imipenemhydrolyzing b-lactamase
(IMI), Serratia marcescens enzyme (SME), and Guiana
extended-spectrum b-lactamase (GES)), Ambler class B
(encoding imipenemase (IMP), Verona integronencoded
metallo-b-lactamase (VIM), New Delhi metallo-b-lactamase
(NDM), German imipenemase (GIM), Sao Paulo metallo-b-
lactamase (SPM), and Seoul imipenemase (SIM)), and Ambler
class D encoding oxacillinase-48 (OXA-48)-type; plasmid-
borne AmpC-like genes encoding CMY and DHA; and ESBL
genes encoding CTX-M, TEM, and SHVusing polymerase chain
reaction (PCR) detection as described previously.17 Outer
membrane porins were isolated according to the rapid pro-
cedure and the profiles were identified using 12% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis followed
by Coomassie blue staining (Gibco-BRL, Grand Island, NY,
USA) as described previously.17
Statistical analyses
Continuous variables were compared with the Student t test
(for normally distributed variables) or the Mann-Whitney U
test (for non-normally distributed variables). Categorical
variables were evaluated with the c2 or two-tailed Fisher
exact test. Odds ratios (ORs) and 95% confidence intervals
(CIs) were calculated for all associations that emerged. Re-
sults are expressed as mean  standard deviation or median
(range; continuous variables), or as percentages of the group
from which they were derived (categorical variables). Two-
tailed tests were used to determine statistical significance;
p< 0.05 was considered significant. To identify independent
predictors of mortality, variables with p < 0.1 on univariate
analysis were included in a multivariate logistic regression
model. All statistical analyses were performed using SPSS
version 18.0 (SPSS Inc., Chicago, IL, USA).
Results
Characteristics of patients who acquired
carbapenem nonsusceptible K. pneumoniae and E.
coli
Carbapenem nonsusceptible K. pneumoniae and E. coli
were identified in 66 patients [median age, 75 years (range,
Table 1 Clinical characteristics of 66 patients with car-
bapenem nonsusceptible Klebsiella pneumoniae and
Escherichia coli in intensive care units
Characteristics n Z 66
Demographic data
Age (y) 71.9  13.7
Male sex 40 (60.6)
LOS prior to isolation, d, median, IQR 27, 15e61
Source of infection
Colonization only 20 (30.3)
Lower respiratory tract infection 22 (33.3)
Catheter infection 7 (10.6)
Urinary tract infection 7 (10.6)
Intra-abdominal infection or
biliary tract infection
6 (9.1)
Skin and soft tissue infection 2 (3.0)
Primary bacteremia 1 (1.5)
Brain abscess 1 (1.5)
Comorbidities
Chronic kidney disease (stage  3) 36 (54.5)
Diabetes mellitus 35 (53.0)
Cerebrovascular disease 24 (36.4)
Renal dialysis 14 (21.2)
Malignancy 13 (19.7)
COPD 11 (16.7)
Immunocompromised statea 10 (15.2)
Liver cirrhosis 6 (9.1)
Charlson Comorbidity Index 4  3
Prior healthcare exposure
Hospitalization in the past 90 d 26 (39.4)
Surgery in the past 90 d 23 (34.8)
Prior use of antimicrobials in the
past 14 d, 3 d
62 (93.9)
Invasive procedure in previous 2 wk
Nasogastric tube 59 (89.4)
Indwelling urinary catheter 52 (78.8)
Indwelling central venous catheter 38 (57.6)
Renal dialysis at isolation 25 (37.9)
Mechanically ventilated at isolation 23 (34.8)
APACHE II score 27  9
Outcome
Presentation with septic shock 14 (21.2)
30-d mortality 25 (37.9)
In-hospital mortality 33 (50.0)
LOS after isolation, d 36.2  36.6
a Immunocompromised patients included recipients of solid
organ transplantation and patients with neutropenia (absolute
neutrophil count < 500/mm3), human immunodeficiency virus
infection, immunosuppressant agents, and steroid therapy
(prednisolone 20 mg/d, >7 days within 4 wk from isolation).
Data are presented as mean  SD or n (%).
APACHE Z Acute Physiology and Chronic Health Evaluation;
COPD Z chronic obstructive pulmonary disease;
IQR Z interquartile range; LOS Z length of hospital stay.
222 Y.-Y. Chang et al.37e96)] during the study period. The demographic and
clinical characteristics and comorbidities of the patients
are shown in Table 1. Infection was diagnosed in 46 patients
and colonization was detected in the remaining 20 patients.The most commonly occurring infectious syndromes were
lower respiratory tract infection (n Z 21, 31.8%), followed
by central venous catheter infection (nZ 8, 12.1%), urinary
tract infection (n Z 7, 10.6%), and intra-abdominal infec-
tion or biliary tract infection (nZ 6, 9.1%). The in-hospital
mortality associated with isolation of nonsusceptible K.
pneumoniae and E. coli was 50%. The mean length of hos-
pital stay after isolation of these pathogens was 36.2 days.
Microbiological characteristics of carbapenem
nonsusceptible K. pneumoniae and E. coli isolates
During the study period, 60 patients had carbapenem non-
susceptible K. pneumoniae strains isolated from one or
more samples including: sputum (n Z 23), urine (n Z 16),
central venous catheter tip (n Z 7), blood (n Z 5), wound
(n Z 3), bronchoalveolar lavage (n Z 2), pleural effusion
(n Z 1), bile (n Z 1), ascites (n Z 1), and brain abscess
(n Z 1). Carbapenem nonsusceptible E. coli strains were
also identified from the bile (n Z 3), sputum (n Z 1),
wound (n Z 1), and urine (n Z 1) of six patients.
The most common mechanisms of carbapenem resis-
tance were the production of AmpC-mediated b-lactamases
or ESBLs plus porin mutations, which were identified in 47
cases (43 K. pneumoniae, 4 E. coli). A total of 19 (28.8%)
isolates had genes that encoded carbapenemases, including
KPC-2 (n Z 14, 13 K. pneumoniae, 1 E. coli), IMP-8 (1 K.
pneumoniae), VIM-1 (3 K. pneumoniae), and NDM-1 (1 E.
coli). Meropenem or imipenem MICs were 8 mg/L for 45
(68.2%) isolates, 4 mg/L for seven (10.6%) isolates, and
2 mg/L for 14 (21.2%) isolates. Most isolates were suscep-
tible to colistin (n Z 61, 92.4%) and tigecycline (n Z 5 4,
81.8%); about half were moderately susceptible to genta-
micin (n Z 32, 48.5%).
Risk factors for 30-day mortality in 46 patients with
infection
The 30-day mortality of 46 patients infected with carba-
penem nonsusceptible K. pneumoniae and E. coli infection
was 50%. Diabetes mellitus (OR 3.56, 95% CI 1.05e12.05,
p Z 0.04), presentation of septic shock (OR 28.6, 95% CI
3.28e249.73, p Z 0.002), appropriate therapy at any time
and for at least 48 hours (OR 0.10, 95% CI 0.02e0.05,
p Z 0.008), and APACHE II score (OR 1.13, 95% CI
1.03e1.23, p Z 0.009) were associated with mortality in
univariate analysis (Table 2). In multivariate analysis
(adjusted for diabetes mellitus, appropriate therapy at any
time and for at least 48 hours, APACHE II score, and pre-
sentation of septic shock), the only independent risk factor
for 30-day mortality was presentation of septic shock (OR
12.14, 95% CI 1.13e129.91, p Z 0.04; Table 3).
We further determined the 30-day mortality rate in pa-
tients who received antimicrobial therapy for at least 48
hours for carbapenem nonsusceptible K. pneumoniae and E.
coli infection. Four cases were excluded from this analysis
because death occurred within 48 hours after receiving
antimicrobial therapy. Table 4 showed the detailed infor-
mation of amtimicrobial therapy among the remaining 42
patients. The 30-day mortality for the 42 patients was
45.2%. Of these 42 patients, the 30-day mortality rate was
Table 2 Univariate analysis of risk factors for 30-day mortality among 46 patients infected with carbapenem nonsusceptible
Klebsiella pneumoniae and Escherichia coli in intensive care units
Variable Non-survivors
n Z 23
Survivors
n Z 23
OR (95% CI) p
Demographic variables
Age (y) 74.0  11.8 68.3  16.1 0.18
Male sex 15 (65.2) 15 (65.2) >0.99
Indwelling central venous catheter 18 (78.3) 15 (65.2) 0.33
Indwelling urinary catheter 20 (87.0) 17 (73.9) 0.27
Nasogastric tube 22 (95.7) 21 (91.3) 0.56
Mechanically ventilated at isolation 11 (47.8) 7 (30.4) 0.23
Renal dialysis at isolation 11 (47.8) 7 (30.4) 0.23
Comorbidities
Diabetes mellitus 16 (69.6) 9 (39.1) 3.56 (1.05e12.05) 0.04
Cerebrovascular disease 4 (17.4) 9 (39.1) 0.11
Heart failure 4 (17.4) 4 (17.4) >0.99
Chronic kidney disease 15 (65.2) 11 (47.8) 0.24
Renal dialysis 5 (21.7) 4 (17.4) 0.71
Liver cirrhosis 3 (13.0) 2 (8.7) 0.64
Malignancy 7 (30.4) 4 (17.4) 0.31
Immunocompromised statea 5 (21.7) 4 (17.4) 0.71
Charlson Comorbidity Index 4.7  2.9 4.6  2.8 0.87
Source of infection
Lower respiratory tract infection 12 (52.2) 10 (43.5) 0.56
Central venous catheter infection 4 (17.4) 3 (13.0) 0.68
Urinary tract infection 3 (13.0) 4 (17.4) 0.68
Intra-abdominal infection or biliary tract infection 3 (13.0) 3 (13.0) >0.99
Skin and soft tissue infection 1 (4.3) 1 (4.3) >0.99
Treatment
Appropriate empirical therapy 9 (39.1) 6 (26.1) 0.35
Appropriate therapy at any time and for at least 48 h 12 (52.2) 21 (91.3) 0.10 (0.02e0.55) 0.008
APACHE II score 32.3  9.4 24.5  7.3 1.13 (1.03e1.23) 0.009
Presentation with septic shock 13 (56.5) 1 (4.3) 28.6 (3.28e249.73) 0.002
Isolation of K. pneumoniae 21 (91.3) 20 (87.0) 0.64
KPC producing isolates 6 (26.1) 2 (8.7) 0.14
a Immunocompromised patients included recipients of solid organ transplantation and patients with neutropenia (absolute neutrophil
count < 500/mm3), human immunodeficiency virus infection, immunosuppressant agents, and steroid therapy (prednisolone 20 mg/day,
>7 days within 4 weeks from isolation).
Data are presented as mean  SD or n (%).
APACHE Z Acute Physiology and Chronic Health Evaluation; CI Z confidence interval; KPC Z Klebsiella pneumoniae carbapenemase;
OR Z odds ratio.
Table 3 Multivariate analysis of risk factors for 30-day
mortality among 46 patients infected with nonsusceptible
Klebsiella pneumoniae and Escherichia coli in intensive
care units
Variable OR (95% CI) p
Presentation with
septic shock
12.14 (1.13e129.91) 0.04
Appropriate therapy
at any time and
for at least 48 h
0.22 (0.03e1.65) 0.14
APACHE II score 1.06 (0.94e1.19) 0.35
Diabetes mellitus 1.09 (0.21e5.68) 0.92
APACHE Z Acute Physiology and Chronic Health Evaluation;
CI Z confidence interval; OR Z odds ratio.
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groups (50.0% vs. 30.4%, p Z 0.29).Discussion
To our knowledge, this is the first study in Taiwan to eval-
uate the clinical and microbiological characteristics of
carbapenem nonsusceptible K. pneumoniae and E. coli in
ICU settings. Infection and colonization were diagnosed in
46 cases and 20 cases, respectively. The major mechanisms
of carbapenem nonsusceptibility were the production of
AmpC-mediated b-lactamases or ESBLs plus outer mem-
brane porin mutations. The 30-day mortality was 50%
among patients infected with these pathogens. The pre-
sentation of septic shock was the only independent risk
factor for 30-day mortality among infected patients. The
Table 4 Detailed antimicrobial therapy of 42 patients
infected with carbapenem nonsusceptible Klebsiella pneu-
moniae and/or Escherichia coli in the intensive care units
Antimicrobial regimens n (%) Mortality,
n (%)
Appropriate antimicrobial
therapy
33 (78.6) 12 (36.3)
Combination therapy 10 (23.8) 5 (50.0)
Tigecycline þ colistin 5 (11.9) 2 (40.0)
Tigecycline þ amikacin 2 (4.8) 1 (50.0)
Tigecycline þ colistin
þ amikacin
2 (4.8) 1 (50.0)
Colistin þ amikacin 1 (2.4) 1 (100.0)
Monotherapy 23 (54.8) 7 (30.4)
Tigecycline 10 (23.8) 2 (20.0)
Carbapenema 6 (14.3) 2 (33.3)
Colistin 3 (7.1) 1 (33.3)
Fluoroquinoloneb 2 (4.8) 1 (50.0)
Aminoglycosidec 2 (4.8) 1 (50.0)
Inappropriate antimicrobial
therapy
9 (21.4) 7 (77.8)
a Two imipenem, three meropenem, one ertapenem.
b One levofloxacin, one ciprofloxacin.
c One gentamicin, one amikacin.
224 Y.-Y. Chang et al.30-day mortality among patients receiving appropriate
antibiotic treatment for at least 48 hours was not signifi-
cantly different between those treated with a combination
of antibiotics and those treated with one antibiotic.
In Taiwan, factors other than carbapenemases still ac-
count for the majority of in vitro resistance mechanisms
responsible for carbapenem nonsusceptibility in Enter-
obacteriaceae.22 One recent nationwide surveillance study
using the same database as in the current study showed
that the main mechanisms of carbapenem nonsusceptibility
used by K. pneumoniae are AmpC b-lactamase or ESBLs and
loss of outer membrane porins. Carbapenemase genes were
detected in 22.3% of all isolates and the majority were KPC-
2eproducing isolates (16.6%).17 Our emphasis was on ICU
settings, where we found a high prevalence of isolates
carrying carbapenemase genes (28.8%). Like a prior study in
Taiwan showing that dissemination of KPC-2 producing K.
pneumoniae originated in ICUs,16 the current study showed
that the spread of KPC-2 producing K. pneumoniae and E.
coli in ICU settings remains an important issue in Taiwan.
In one prospective surveillance study of ICU patients in
Israel (from 2007 to 2008), recent surgery and severity of
illness [Sequential Organ Failure Assessment (SOFA) score]
were the independent risk factors for carbapenem-resistant
K. pneumoniae acquisition.15 In another retrospective study
of carbapenem resistant K. pneumoniae infections in the
ICUs of Greece (from 2009 to 2010), mortality at 14 days
was significantly associated with patient age.23 In our study,
septic shock was the only independent risk factor for 30-
day mortality, suggesting that critically ill patients infec-
ted with carbapenem nonsusceptible E. coli or K. pneu-
moniae have poor prognosis. Thus, there might be a need
for new therapeutic management in patients with septic
shock.Nonrandomized studies suggest that combination anti-
biotic treatment, especially including carbapenems, in-
creases the survival of critically ill patients with severe
infections caused by carbapenemase-producing Klebsiella
spp.24 In a recent multicenter study in the ICUs of Greece
during 2009 to 2010, mortality was lower in patients
receiving combination therapy than in patients receiving
other treatment regimens, but the difference was not
statistically significant.23 Likewise, in our study, the 30-day
mortality rate was similar between combination and single
therapy groups (50.0% vs. 30.4%, p Z 0.29). Complicated
underlying severity in these critically ill patients and small
number of cases for evaluation may explain why no dif-
ference is found.
One recent study conducted in a medical center in
central Taiwan during 2010e2011 found that 60% of pa-
tients with ertapenem-resistant Enterobacteriaceae
required intensive care.25 The overall 30-day mortality rate
was 40.8%. In the current study, the mortality rate was
higher in patients infected with carbapenem non-
susceptible K. pneumoniae and E. coli in an ICU setting. Our
overview of clinical outcomes and analysis of the risk fac-
tors for mortality suggest that specific infection control
strategies for CRE, periodic targeted surveillance, and
development of new effective antimicrobial drugs may be
the appropriate measures for dealing with infections
caused by CRE in ICU settings in the future.
The main limitation of this study is that clinical data
were obtained retrospectively from medical records. The
practices of physicians or accuracy of information may vary.
The retrospective design and small sample size because of
the limited occurrence of these infections or colonization
may have underpowered the study, reducing the power of
the analysis to identify risk factors and detect significant
differences.
In conclusion, patients with carbapenem nonsusceptible
K. pneumoniae and E. coli are associated with high mor-
tality rates (50%) in ICU settings. Carbapenemase genes
were detected in 28.8% of all isolates. Septic shock was the
only independent risk factor identified for 30-day mortality.
Traditional forms of therapeutic management might not be
adequate to deal with this critical problem. Further large-
scale well-designed randomized controlled trials of thera-
peutic interventions for CRE infection are needed to tackle
this challenge.Conflicts of interest
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